Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the pharma industry. This time, you get to discover 5 hand-picked startups developing cardiovascular drugs.
Global Startup Heat Map: 5 Top Startups developing Cardiovascular Drugs
The 5 pharma startups you will explore below are chosen based on our data-driven startup scouting approach, taking into account factors such as location, founding year, and relevance of technology, among others. This analysis is based on the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform, covering over 1.3 million startups & scaleups globally.
The Global Startup Heat Map below highlights the 5 startups developing cardiovascular drugs our Innovation Researchers curated for this report. Moreover, you get insights into regions that observe a high startup activity and the global geographic distribution of the 295 companies we analyzed for this specific topic.
TransThera Biosciences works on Small Molecule Drugs
Globally, cardiovascular diseases are the single largest cause of death. That is why startups are developing novel drugs for a range of different cardiovascular diseases, including unmet clinical needs. Although biologics are on the rise, small molecule drugs still constitute the majority of these drugs. Inhibitors downregulate molecular determinants of disease, enabling precise treatment of cardiovascular indications.
TransThera Biosciences is a Chinese startup that develops small molecule drugs to use for the treatment of cardiovascular diseases, cancer, and inflammation. TT-00920, one of the drugs in the startup’s pipeline, is a potent, selective, and low brain-penetrant small molecule inhibitor. The drug inhibits PDE9, a phosphodiesterase enzyme that is highly elevated during heart failure.
CinCor Pharma develops an Aldosterone Synthase Inhibitor
Hypertension and high blood pressure constitute a growing global public health crisis. Patients suffering from resistant hypertension are more likely to suffer from myocardial infarction, congestive heart failure, and stroke. Novel therapeutics target hormonal systems involved in the development of cardiovascular diseases. Aldosterone synthase inhibitors, for example, present a new approach to lowering blood pressure, as well as mitigating other adverse effects of aldosterone accumulation.
US-based startup Cincor Pharma develops novel therapeutics for cardiovascular diseases. CIN-107, the startup’s lead drug candidate, is a highly selective aldosterone synthase inhibitor. The drug targets the renin-angiotensin-aldosterone system (RAAS), a hormonal system commonly targeted by cardiovascular therapeutics. Besides, the startup also explores drugs for metabolic and kidney diseases.
Cardiol Therapeutics works on Cannabidiol (CBD)
Medical cannabis is on the rise, with pharma startups applying it to a wide range of diseases. Cannabidiol has been demonstrated to exhibit anti-inflammatory activity in models of cardiovascular disease. Therefore, pharma startups are investigating the use of CBD for a range of cardiovascular indications such as acute myocarditis and heart failure.
Canadian Cardiol Therapeutics works on anti-inflammatory therapies to treat cardiovascular diseases. The startup’s pharmaceutically produced cannabidiol formulation is ultrapure grade and essentially free of tetrahydrocannabinol (THC). CardiolRx, a high concentration cannabidiol oral formulation, is under investigation for the treatment of acute inflammatory heart disease. The startup is also undertaking clinical trials to investigate the therapeutic efficacy of CardiolRx on myocardial recovery in patients with acute myocarditis.
Heartseed works with Induced Pluripotent Stem Cells (iPSCs)
Induced pluripotent stem cells are stem cells reprogrammed from differentiated cells. iPSCs ensure a virtually unlimited supply of any kind of human cells for therapeutic applications. Additionally, these cells are introduced directly into the patient’s body and produce differentiated cells in vivo. This makes them suitable for regenerative therapeutics for a wide range of clinical indications.
Japanese startup Heartseed derives highly purified ventricular cardiomyocytes from iPSCs. The startup’s patented purification method eliminates undifferentiated cells and non-cardiomyocytes, reducing the risk of teratoma formation and arrhythmia. HS-001, the startup’s lead transplantation therapy, is in preclinical development for the treatment of heart failure with reduced ejection fraction (HFrEF).
Verve Therapeutics focuses on Gene Therapy
The falling costs of gene sequencing, as well as gene editing technologies, are making gene therapy commercially viable. As a result, pharma startups are exploring gene therapy as an alternative approach to unmet clinical needs in cardiology. Potential targets include cardiac and peripheral ischemia, heart failure, and coronary heart disease. Pharma startups and companies are working on gene therapy delivery mechanisms for the treatment of these and other cardiovascular indications.
Verve Therapeutics is a US-based startup that offers gene therapies for coronary heart disease. The startup’s lead candidate VERVE-101 uses adenine base editing to knock out the PCSK9 gene. As a result, it lowers the level of low-density lipoprotein cholesterol (LDL-C) for the treatment of coronary heart disease (CHD). Other gene therapies from the startup regulate the levels of triglyceride-rich lipoprotein (TRL) and lipoprotein(a) (Lp(a)).
Discover more Pharma startups
To keep you up-to-date on the latest technology and emerging solutions, we provide you with actionable innovation intelligence – quickly and exhaustively. You can download our free Pharma Industry Report and discover new business opportunities or save your time & let us look into your areas of interest. We provide you with an exhaustive overview of new startups, scaleups & emerging technologies that matter to you.